Pharmafile Logo
Pharmafocus logo
Advanced Search

oncology

Showing 15 posts of 301 posts found.

img_4190-e1376666350337-web

Accord Healthcare launches thalidomide for multiple myeloma treatment

March 23, 2021
Manufacturing and Production MHRA, oncology

Accord Healthcare has announced the UK launch of a generic thalidomide, which is used in combination with melphalan and prednisone, …

News

Novartis prostate cancer treatment sees positive Phase III results

March 23, 2021
Manufacturing and Production Novartis, oncology

Novartis has today announced positive results from its Phase III VISION study with 177Lu-PSMA-617, seeing significant improvements in overall survival …

News
roche__tree

Roche lung cancer treatment reports promising results in Phase III

March 22, 2021
Sales and Marketing Roche, oncology

Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in …

News

NICE recommends new triple therapy for multiple myeloma patients

March 19, 2021
Medical Communications NHS England, NICE, oncology

A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma, following a …

News

AstraZeneca & MSD ovarian cancer drug combination approved by NICE

March 19, 2021
Medical Communications AstraZeneca, MSD, NICE, oncology

A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …

News

Complix and I-Mab sign deal to develop alphabody cancer therapies

March 11, 2021
Cancer, Complix, oncology

Biopharmaceutical company Complix has signed a drug discovery deal with I-Mab Biopharma, a clinical-stage company focused on the discovery, development, …

News
shutterstock_138095450

Gilead and Jounce Therapeutics forge immuno-oncology partnership worth a potential $700m+

September 2, 2020
Research and Development, Sales and Marketing Gilead, jounce, oncology, pharma

Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million. The primary drive …

News
gilead_hq_at_stockley_park_london_2

Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal

March 3, 2020
Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma

Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …

News
6684097669_b859b7ea96_b

E. coli strain in the gut may increase risk of bowel cancer, new study finds

February 28, 2020
Medical Communications Cancer, E. coli, bowel cancer, bowels, cancer research, e coli, oncology

A type of E. coli infection may increase a person’s chance of developing bowel cancer, according to a new study …

News

China approves Roche cancer drug Kadcyla

January 22, 2020
Business Services China, Roche, breast cancer, cancer treatment, oncology

China has approved the import of Roche’s drug for breast cancer, just after it recently won expanded approval in the …

News

Novartis establishes its new legal entity in Vietnam

January 22, 2020
Research and Development Novartis, Novartis Vietnam, oncology, pharma

Novartis has inaugurated its new legal entity in Vietnam, Novartis Vietnam Co Ltd, and has become one of the first …

News
1201709115_133b3927a3_b

Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery

January 10, 2020
Medical Communications Bayer, Exscientia, oncology

Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. …

News
china_block_001_takeda_0

Takeda commits to advancing treatments for rare bleeding disorders and cancer

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology

Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …

News
merck-keytruda

Prostate Cancer ‘super responders’ could live for two more years on Keytruda

November 28, 2019
Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer

Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …

News

FDA approves AstraZeneca’s Calquence in chronic lymphoma

November 25, 2019
Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology

The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …

News

Latest content

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024